Instrument Inactif

Communiqués StemCells Inc Nasdaq

Actions

US85857R2040

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

09/06	Microbot Medical Inc. annonce l'adoption du système robotique endovasculaire Liberty par un réseau de santé de premier plan dans le Michigan	CI
02/06	Microbot Medical Inc. s'implante en Caroline du Nord avec l'adoption du système robotique endovasculaire LIBERTY	CI

Communiqués

09/06	Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System	GL
02/06	Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System	GL
26/05	Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic System	GL
15/05	Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu	GL
14/05	Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026	GL
05/05	Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites	GL
01/05	Microbot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia	AQ
30/04	Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)	GL
22/04	Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®	GL
15/04	Microbot Medical to Highlight Commercial Achievements Leading to the Full Market Release of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference	AQ
14/04	Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference	GL
13/04	Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting	GL
26/03	Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System	GL
26/03	Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System	AQ
24/03	Microbot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical Journal	GL
17/03	Microbot Medical® to Participate at the 38th Annual Roth Conference	GL
10/03	Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time	GL
04/03	Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation	GL
03/03	Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event	GL
03/03	Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event	AQ
24/02	Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System	GL
19/02	Microbot Medical®’s LIBERTY® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured at an Industry Leading Innovation Conference	GL
12/02	Microbot Medical®’s LIBERTY® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management Conference	GL
05/02	Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption	GL
05/02	Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption	AQ